Prasad Vaccine Development

From Concept to Clinic
1. Auflage 2022
ISBN: 978-1-83916-257-2
Verlag: Royal Society of Chemistry
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, Band Volume 3, 304 Seiten

Reihe: Drug Development and Pharmaceutical Science

Vaccine development is a complex and time consuming process that differs from the development of conventional pharmaceuticals. Primarily, vaccines are intended for use in healthy individuals as a preventative measure, requiring a long and rigorous process of research and many years of testing and development prior to clinical trials and regulatory approval. The average time for the development of vaccines to clinical is 12 to 15 years. Vaccine Development: From Concept to Clinic is a detailed overview of the development of new vaccines, covering the entire process and addresses all classes of vaccines from a processing, development and regulatory viewpoint. Utilising successful case studies the book will provide insight to the issues scientists face when producing a vaccine, the steps involved and will serve as an ideal reference tool regarding state-of-the-art vaccine development. This book is an ideal companion for any researchers working in vaccine discovery and development or with an interest in the field.

Autoren/Hrsg.

Prasad, A Krishna

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Chemie Organische Chemie
• Wirtschaftswissenschaften Wirtschaftssektoren & Branchen Fertigungsindustrie Pharmaindustrie
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Pharmazeutische Technologie

Inhaltsverzeichnis

Vaccine Development: From Concept to Clinic;

Pre-clinical Safety Assessment Considerations for Vaccine Development;

Clinical Trials in the Development of Vaccines for Infectious Diseases;

Clinical Trials in Immunotherapeutic Vaccine Development;

Pathogenesis and Immunity of SARS-CoV-2 and Vaccination Programs against COVID-19;

High Throughput Assays for Clinical Development;

Virus-like Particle Based Vaccines: GARDASIL®;

Cell Culture-based Influenza Vaccine Development;

Conjugate Vaccines: Design and Development Considerations;

Vaccine Adjuvants: Mechanisms of Action;

Development Considerations for Final Dosage Forms: Mucosal Bacterial Vaccines;

Exploiting Glycans in Vaccine Design;

The PATH Experience in Vaccine Development Partnerships with Manufacturers from Emerging Markets

Über Autor(innen)

Prasad, A Krishna
Citranvi LLC., USA